Urticaria is commonly known as rubella. It is a localized edema response due to dilation of the skin and mucosal small blood vessels and increased permeability. It usually subsides within 2 to 24 hours, but new rashes occur repeatedly. The course of the disease is delayed for several days to several months. More common in clinically.
Due to the COVID-19 pandemic, the global Urticaria Drug market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Urticaria Drug market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Urticaria Drug landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Acute Urticaria accounting for % of the Urticaria Drug global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital Pharmacies segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Urticaria Drug include Johnson and Johnson Services, Amneal Pharmaceuticals, Pfizer, Taro Pharmaceutical Industries Novartis AG, Akorn, Teva Pharmaceutical Industries, Genentech and Xolair, etc. In terms of revenue, the global 3 largest players have a % market share of Urticaria Drug in 2021.
This report focuses on Urticaria Drug volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Urticaria Drug market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Urticaria Drug Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Acute Urticaria
Chronic Urticaria
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Johnson and Johnson Services
Amneal Pharmaceuticals
Pfizer
Taro Pharmaceutical Industries Novartis AG
Akorn
Teva Pharmaceutical Industries
Genentech
Xolair